search
Back to results

Treatment Strategy of Vasovagal Syncope (CAMPAIGN)

Primary Purpose

Syncope, Vasovagal

Status
Recruiting
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
Cardioneuroablation
Midodrine Oral Tablet
patients educaiton
Sponsored by
China National Center for Cardiovascular Diseases
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Syncope, Vasovagal focused on measuring Vasovagal syncope, Cardioneuroablation, Midodrine

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Age ≥ 18 years of age Calgary Syncope Symptom Score ≥ -2 points Positive response to head-up tilt test With syncope episodes more than 3 times in the preceding year Willingness to comply with follow-up requirements and to sign the informed consent Exclusion Criteria: Complied with other causes of syncope, including postural hypotension, aortic stenosis, sick sinus node syndrome, high-grade atrioventricular block, ventricular arrhythmias, pulmonary hypertension, hypertrophic cardiomyopathy, transient ischemic attack, epilepsy, sequelae of cerebral infarction or cerebral hemorrhage, subclavian vein steal syndrome and drug-induced syncope. Complied with congenital heart disease, valvular heart disease, cardiomyopathy, and diabetes. History of cardiac catheter ablation, peacemaker implantation and cardiac surgery. History of midodrine usage, or compiled with contradiction of midodrine, including urine retention, hypertension (Bp≥140/90mmHg), glaucoma, renal dysfunction. NYHA class IV congestive heart failure or LVEF < 35% Pregnancy or breast-feeding Life expectancy <1 year for any medical condition

Sites / Locations

  • Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical CollegeRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Experimental group: Cardioneuroablation

Control group: Midodrine

Arm Description

In this arm, the catheter ablation of the GPs will be performed in the order of LSGP, LIGP, RIGP, left atrial RAGP、right atrial RAGP. Patient education includes fully informing patients of the benign prognosis of vasovagal syncope, and educating patients to avoid triggering factors as much as possible. At the same time, the patient should be taught how to cope with the impending syncope with physical counter-pressure maneuvers and dietary suggestions that emphasize fluid and sodium intake.

In this arm, Midodrine will be applied without the following contraindications: hypertension, chromaffin cell carcinoma, acute nephritis, severe renal dysfunction, glaucoma, prostatic hyperplasia with urinary retention, mechanical urinary obstruction, hyperthyroidism. Patient education includes fully informing patients of the benign prognosis of vasovagal syncope, and educating patients to avoid triggering factors as much as possible. At the same time, the patient should be taught how to cope with the impending syncope with physical counter-pressure maneuvers and dietary suggestions that emphasize fluid and sodium intake.

Outcomes

Primary Outcome Measures

Number of Participants with syncope recurrence during follow-up
Syncope was defined as a transient loss of consciousness and complete recovery in a very short time.

Secondary Outcome Measures

Number of Participants with pre-syncope during follow-up
Pre-syncope was defined as the prodrome before syncope, such as dizziness, sweating,dyspnea, and paleness, and patients did not actually fall down. We documented each time that syncope occurred. The severeity of the prodrome will be assessed with a standardized questionnaire CPF.
Quality of life measure by Impact of Syncope on Quality of Life(ISQL)questionnaire
The difference in quality of life between the two groups as compared to baseline by using the standardized ISQL (Impact of Syncope on Quality of Life) questionnaire. The ISQL score was ranged from 0 to 57 points, and higher points represented more severe impaired quality of life.
Quality of life measure by Impact of Syncope on Quality of Life(ISQL)questionnaire
The difference in quality of life between the two groups as compared to baseline by using the standardized ISQL (Impact of Syncope on Quality of Life) questionnaire. The ISQL score was ranged from 0 to 57 points, and higher points represented more severe impaired quality of life.
Results of Head-up tilt test
The difference in the rate of head-up tilt test induced syncope between the two groups. The positive results of head-upright tilt test were defined by VASIS standard. The examination will be performed at each investigative center.
Blood pressure measured with 24 hours monitoring
The difference in blood pressure between the two groups as compared to baseline. Both systolic and diastolic blood pressure were assessed. The device provided to patients prior to discharge or at outpatient visits will be used for this assessment.
Blood pressure measured with 24 hours monitoring
The difference in blood pressure between the two groups as compared to baseline. Both systolic and diastolic blood pressure were assessed. The device provided to patients prior to discharge or at outpatient visits will be used for this assessment.

Full Information

First Posted
March 9, 2023
Last Updated
July 5, 2023
Sponsor
China National Center for Cardiovascular Diseases
Collaborators
Beijing Chao Yang Hospital, RenJi Hospital, Yeditepe University Hospital, First Affiliated Hospital Xi'an Jiaotong University, First Affiliated Hospital, Sun Yat-Sen University, Ningbo No. 1 Hospital, Fuwai Yunnan Cardiovascular Hospital, Henan Provincial People's Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT05803148
Brief Title
Treatment Strategy of Vasovagal Syncope
Acronym
CAMPAIGN
Official Title
Effect of Cardioneuroablation vs Midodrine on Syncope Recurrence Among Patients With Vasovagal Syncope: The CAMPAIGN Randomized Clinical Trial
Study Type
Interventional

2. Study Status

Record Verification Date
July 2023
Overall Recruitment Status
Recruiting
Study Start Date
April 5, 2023 (Actual)
Primary Completion Date
December 30, 2024 (Anticipated)
Study Completion Date
December 30, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
China National Center for Cardiovascular Diseases
Collaborators
Beijing Chao Yang Hospital, RenJi Hospital, Yeditepe University Hospital, First Affiliated Hospital Xi'an Jiaotong University, First Affiliated Hospital, Sun Yat-Sen University, Ningbo No. 1 Hospital, Fuwai Yunnan Cardiovascular Hospital, Henan Provincial People's Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This is a prospective, international multi-center, open-labeled, randomized trial. The investigator speculated that CNA prevents more patients with moderate to severe VVS from syncope recurrence compared to midodrine.
Detailed Description
Nearly 40% of people faint at least once in their life, and vasovagal syncope (VVS) is the most common cause. Study shows that VVS accounts for 66% of syncope in the Emergency Room. The early peak incidence is around 15 years for young women and a later significant rise in visits for both sexes over the age of 65 years. Patients with frequent syncope have a markedly reduced quality of life, similar to that of patients with severe rheumatoid arthritis or chronic low back pain. Vasovagal syncope is characterized by paroxysmal hypotension and/or bradycardia. Multiple hypotheses have been suggested as the mechanism of VVS, hence the treatment was diverse. The current therapy suggested by guidelines includes diet, counter-pressure maneuvers, beta-blockers, fludrocortisone, serotonin reuptake inhibitors, midodrine, and permanent pacemakers. Cardioneuroablation (CNA) which modified the cardiac autonomic nervous system through catheter ablation shows encouraging results in preventing syncope recurrence. Experience from our center also suggested that CNA was highly effective, with a syncope-free rate of nearly 80% for 4-year follow-up; however, the studies were non-randomized with no control group. A recent single-center randomized control study has reported that CNA was superior to non-pharmacology therapy for syncope prevention. The investigators are hereby willing to compare the effectiveness of CNA to drug therapy in a multi-center randomized control fashion. The objective of this trial is to determine the role of CNA and midodrine therapy in the prevention of syncope recurrence in patients with vasovagal syncope and provide evidence for clinical treatment strategies. Participants will be randomized to either CNA plus patient education (diet, avoidance trigger, physical counter-pressure maneuvers) or midodrine therapy plus patient education. Randomization will be carried out with interactive web response system stratified by center. The participants were followed up at 7 days, 3 months, 6 months, 12 months and 24 months respectively after ablation procedure, to observe whether there were recurrent syncope and /or pre-syncope (including the time and frequency of recurrent syncope, inducing factors, and whether complicated with fall injury, etc.), and to reassessed tilt test, 24-hour ambulatory electrocardiogram and fill in Euroqol (EQ-5D) and ISQL quality of life score form. To evaluate the safety and efficacy of cardiac nerve ablation in the prevention of refractory vasovagal syncope. The tilt test, the changes of vagus nerve function and the improvement of quality of life before and after were analyzed and compared.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Syncope, Vasovagal
Keywords
Vasovagal syncope, Cardioneuroablation, Midodrine

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
184 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Experimental group: Cardioneuroablation
Arm Type
Experimental
Arm Description
In this arm, the catheter ablation of the GPs will be performed in the order of LSGP, LIGP, RIGP, left atrial RAGP、right atrial RAGP. Patient education includes fully informing patients of the benign prognosis of vasovagal syncope, and educating patients to avoid triggering factors as much as possible. At the same time, the patient should be taught how to cope with the impending syncope with physical counter-pressure maneuvers and dietary suggestions that emphasize fluid and sodium intake.
Arm Title
Control group: Midodrine
Arm Type
Active Comparator
Arm Description
In this arm, Midodrine will be applied without the following contraindications: hypertension, chromaffin cell carcinoma, acute nephritis, severe renal dysfunction, glaucoma, prostatic hyperplasia with urinary retention, mechanical urinary obstruction, hyperthyroidism. Patient education includes fully informing patients of the benign prognosis of vasovagal syncope, and educating patients to avoid triggering factors as much as possible. At the same time, the patient should be taught how to cope with the impending syncope with physical counter-pressure maneuvers and dietary suggestions that emphasize fluid and sodium intake.
Intervention Type
Procedure
Intervention Name(s)
Cardioneuroablation
Other Intervention Name(s)
Cardiac ganglion plexus ablation
Intervention Description
The left atrium model was established under the guidance of three-dimensional mapping. Atrial septum puncture、left atrium mapping and right atrium mapping will be performed according to standard EP lab protocol. The location of GPs will be detected with HAFE potential (duration ≥ 50ms, deflections ≥ 8 times, amplitude ≥ 1.95mV) and high frequency stimulation (HFS; 30 Hz, 20 mV, pulse width 2ms) through positive vasovagal response (transient ventricular asystole, atrioventricular block, or R-R interval increased by 30%) . Saline Irrigated-tip catheter with pressure monitoring will be applied for the procedure, and radiofrequency energy is limited to 40W and 43℃ for at least 30s at each site. The ablation endpoint for each GP is defined as the complete elimination of all targeted HAFE potential and elimination of positive vasovagal response. The endpoint of the procedure was that the heart rate reach 75% of the maximum heart rate in atropine test.
Intervention Type
Drug
Intervention Name(s)
Midodrine Oral Tablet
Other Intervention Name(s)
Midodrine pill
Intervention Description
Midodrine will start dosing with 5 mg of the study drug 3 times daily, 4 hours apart, during daylight hours.Dose with be adjusted within a range of 2.5 mg twice daily, 4 hours apart, up to 10 mg, 3 times daily, every 4 hours. The optimal dose ranging be completed within the first 2 weeks. If intolerable symptoms persisted despite dose reductions, the drug will be withdrawn, and the patient was released from the study.
Intervention Type
Behavioral
Intervention Name(s)
patients educaiton
Intervention Description
Patient education includes fully informing patients of the benign prognosis of vasovagal syncope, and told patients to avoid triggering factors as much as possible . At the same time, the patient should be taught how to cope with the impending syncope with physical counter-pressure maneuvers and dietary suggestions that emphasize fluid and sodium intake.
Primary Outcome Measure Information:
Title
Number of Participants with syncope recurrence during follow-up
Description
Syncope was defined as a transient loss of consciousness and complete recovery in a very short time.
Time Frame
12 month after randomization
Secondary Outcome Measure Information:
Title
Number of Participants with pre-syncope during follow-up
Description
Pre-syncope was defined as the prodrome before syncope, such as dizziness, sweating,dyspnea, and paleness, and patients did not actually fall down. We documented each time that syncope occurred. The severeity of the prodrome will be assessed with a standardized questionnaire CPF.
Time Frame
12 month after randomization
Title
Quality of life measure by Impact of Syncope on Quality of Life(ISQL)questionnaire
Description
The difference in quality of life between the two groups as compared to baseline by using the standardized ISQL (Impact of Syncope on Quality of Life) questionnaire. The ISQL score was ranged from 0 to 57 points, and higher points represented more severe impaired quality of life.
Time Frame
6 month after randomization
Title
Quality of life measure by Impact of Syncope on Quality of Life(ISQL)questionnaire
Description
The difference in quality of life between the two groups as compared to baseline by using the standardized ISQL (Impact of Syncope on Quality of Life) questionnaire. The ISQL score was ranged from 0 to 57 points, and higher points represented more severe impaired quality of life.
Time Frame
12 month after randomization
Title
Results of Head-up tilt test
Description
The difference in the rate of head-up tilt test induced syncope between the two groups. The positive results of head-upright tilt test were defined by VASIS standard. The examination will be performed at each investigative center.
Time Frame
12 month after randomization
Title
Blood pressure measured with 24 hours monitoring
Description
The difference in blood pressure between the two groups as compared to baseline. Both systolic and diastolic blood pressure were assessed. The device provided to patients prior to discharge or at outpatient visits will be used for this assessment.
Time Frame
6 month after randomization
Title
Blood pressure measured with 24 hours monitoring
Description
The difference in blood pressure between the two groups as compared to baseline. Both systolic and diastolic blood pressure were assessed. The device provided to patients prior to discharge or at outpatient visits will be used for this assessment.
Time Frame
12 months after ablation procedure

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age ≥ 18 years of age Calgary Syncope Symptom Score ≥ -2 points Positive response to head-up tilt test With syncope episodes more than 3 times in the preceding year Willingness to comply with follow-up requirements and to sign the informed consent Exclusion Criteria: Complied with other causes of syncope, including postural hypotension, aortic stenosis, sick sinus node syndrome, high-grade atrioventricular block, ventricular arrhythmias, pulmonary hypertension, hypertrophic cardiomyopathy, transient ischemic attack, epilepsy, sequelae of cerebral infarction or cerebral hemorrhage, subclavian vein steal syndrome and drug-induced syncope. Complied with congenital heart disease, valvular heart disease, cardiomyopathy, and diabetes. History of cardiac catheter ablation, peacemaker implantation and cardiac surgery. History of midodrine usage, or compiled with contradiction of midodrine, including urine retention, hypertension (Bp≥140/90mmHg), glaucoma, renal dysfunction. NYHA class IV congestive heart failure or LVEF < 35% Pregnancy or breast-feeding Life expectancy <1 year for any medical condition
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
yan Yao, PhD
Phone
13901121319
Email
ianyao@263.net.cn
First Name & Middle Initial & Last Name or Official Title & Degree
lihui Zheng, PhD
Phone
13910617612
Email
zhenglihui@263.net
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
yan Yao, PhD
Organizational Affiliation
Fuwai Hospital, National Center for Cardiovascular Diseases
Official's Role
Study Chair
Facility Information:
Facility Name
Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College
City
Beijing
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yan Yao, MD PhD
Phone
+86-1390-1121-319
Email
ianyao@263.net.cn

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
34896621
Citation
Tu B, Wu L, Hu F, Fan S, Liu S, Liu L, Ding L, Zheng L, Yao Y. Cardiac deceleration capacity as an indicator for cardioneuroablation in patients with refractory vasovagal syncope. Heart Rhythm. 2022 Apr;19(4):562-569. doi: 10.1016/j.hrthm.2021.12.007. Epub 2021 Dec 9.
Results Reference
result
PubMed Identifier
34339231
Citation
Sheldon R, Faris P, Tang A, Ayala-Paredes F, Guzman J, Marquez M, Morillo CA, Krahn AD, Kus T, Ritchie D, Safdar S, Maxey C, Raj SR; POST 4 investigators. Midodrine for the Prevention of Vasovagal Syncope : A Randomized Clinical Trial. Ann Intern Med. 2021 Oct;174(10):1349-1356. doi: 10.7326/M20-5415. Epub 2021 Aug 3.
Results Reference
result
PubMed Identifier
31330187
Citation
Hu F, Zheng L, Liang E, Ding L, Wu L, Chen G, Fan X, Yao Y. Right anterior ganglionated plexus: The primary target of cardioneuroablation? Heart Rhythm. 2019 Oct;16(10):1545-1551. doi: 10.1016/j.hrthm.2019.07.018. Epub 2019 Jul 19.
Results Reference
result

Learn more about this trial

Treatment Strategy of Vasovagal Syncope

We'll reach out to this number within 24 hrs